New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
07:13 EDTGWPHGW Pharmaceuticals reports promising signs of efficacy, safety in CBD candidate
GW Pharmaceuticals announced physician reports of efficacy and safety data on 27 children and young adults with treatment-resistant epilepsy who have been treated with GW's investigational cannabidiol, or CBD, product candidate, Epidiolex, for a period of 12 weeks. The treatment-resistant patients suffer from a range of epilepsies in which current anti-epileptic drugs have been unsuccessful in adequately controlling seizures, and included such severe forms of epilepsy as Dravet syndrome and Lennox-Gastaut syndrome. Uncontrolled data from two hospital sites in the United States that were generated under expanded access Investigational New Drug applications authorized by the FDA were made available to the company.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
18:20 EDTGWPHOn The Fly: After Hours Movers
Subscribe for More Information
17:26 EDTGWPHGW Pharmaceuticals CEO says market for Epidiolex may be expanded over time
Subscribe for More Information
14:55 EDTGWPHGW Pharma analyst day positive, reason for sell-off unclear, says Piper Jaffray
Subscribe for More Information
08:07 EDTGWPHGW Pharmaceuticals data should 'silence the doubters,' says Piper Jaffray
Subscribe for More Information
07:15 EDTGWPHGW Pharmaceuticals says Epidiolex physician reports show signals of efficacy
Subscribe for More Information
07:11 EDTGWPHGW Pharmaceuticals announces preliminary topline results of Phase 2a trial
Subscribe for More Information
06:38 EDTGWPHGW Pharmaceuticals to host research and development day
Subscribe for More Information
October 8, 2014
11:23 EDTGWPHGW Pharmaceuticals slides after U.K. body recommends against use of Sativex
Subscribe for More Information
10:24 EDTGWPHGW Pharmaceuticals weakness on NICE guidance 'irrational,' says Piper Jaffray
Subscribe for More Information
10:04 EDTGWPHNICE guidance does not recommend use of Sativex in MS care
In an update to its original 2003 guideline, the U.K.'s National Institute for Health and Care Excellence has set out how people with multiple sclerosis, or MS, can receive better care. In the update, NICE recommends that people with suspected MS should be referred to a consultant neurologist. MS should not be diagnosed on the basis of MRI findings alone and only a consultant neurologist should make the diagnosis of MS. The guidance does not recommend the use of the cannabinoid drug Sativex, manufactured by GW Pharmaceuticals (GWPH), or fampridine as they provide only a modest benefit at a significant cost to the NHS, NICE stated. Shares of GW Pharmaceuticals are down 7% in early trading following the publication of NICE's new guidelines.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use